Astellas Pharma : Supplementary Documents (Q1/FY2022)

Supplementary Documents [IFRS]

Financial results for the first three months of the fiscal year 2022 (FY2022)

	Astellas Pharma Inc.
-	Q1/FY2022 Financial Results
-	Pipeline list

Cautionary Notes

-

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets,

1. currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new
   products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
   Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

S-1

S-2

S-3

S-4

S-5